Subscribe
Contact Us
About Us
Advertise
Home
News
News from MM&M
Off the Wire
Newsletters
PMD Profiles
Agency Creative Showcase
Publication Connection
PMD Marketplace
Careers
About Us
Additional Resources
MM&M
MM&M Jobs
MAHF
Voi Consulting
Advertise
Subscribe
Get Listed
Additional Resources
RSS
|
Login
|
Register
Pharmaceutical
Pfizer Discontinues A Phase 3 Study Of Figitumumab In Previously Treated Patients With Advanced Non-Small Cell Lung Cancer
March 11, 2010
Findings will Contribute to Understanding and Future Study of Figitumumab
Abbott Receives U.S. FDA Approval for New Cataract Multifocal Intraocular Lens
March 10, 2010
Premium Lens Provides Medicare Beneficiaries With New Option
Abbott Enhances Pharmaceutical Pipeline with Acquisition of Facet Biotech
March 09, 2010
Abbott will acquire Facet for $27 per share in cash
Lilly to Acquire European Rights to Pfizer Animal Health Assets
March 08, 2010
Deal Provides Strategic Fit For Elanco, Lilly's Animal Health Division
Columbia Laboratories Enters into Purchase and Collaboration Agreement with Watson Pharmaceuticals for Progesterone Franchise
March 04, 2010
Watson to acquire rights to CRINONE® and PROCHIEVE®
EKR Therapeutics Appoints John Bailye as Interim President & Chief Executive Officer
March 03, 2010
Howard Weisman leaves the company
Novo Nordisk Receives FDA Approval for Norditropin(R) FlexPro(R) for Growth Hormone Treatment
March 03, 2010
Easy to use and simple treatment option for growth hormone disorders
Pfizer And Medivation Announce Results From Two Phase 3 Studies In Dimebon (latrepirdine*) Alzheimer's Disease Clinical Development Program
March 03, 2010
Phase 3 study did not meet main or secondary goals
Astellas Pharma Inc. Commences Tender Offer to Acquire All Outstanding Shares of OSI Pharmaceuticals for $52 per Share in Cash
March 02, 2010
Astellas Files Lawsuit Against OSI
Transdel Pharmaceuticals Appoints Terry Nida as Chief Business Officer
March 01, 2010
Mr. Nida has more than 30 years of pharmaceutical industry experience
Astellas Pharma Inc. Offers to Acquire OSI Pharmaceuticals for $52.00 Per Share in Cash
March 01, 2010
Astellas to build a world-class oncology platform
Shire Announces FDA Approval of VPRIV(TM) (velaglucerase alfa for injection) for the Treatment of Type 1 Gaucher Disease
February 26, 2010
Company Announces New Enhancements to Patient Assistance Programs in the United States
Adamis Pharmaceuticals Signs Agreement to Acquire Prostate Cancer Drug Candidates
February 25, 2010
Adamis to retain U.S. rights and out-license other geographic territories
FDA Advisory Committee Recommends Approval Of XIFAXAN® (rifaximin) Tablets, 550 Mg for Maintenance of Remission of Hepatic Encephalopathy
February 23, 2010
FDA has issued an action date of March 24, 2010
Forest Laboratories Receives Decision from FDA for Supplemental New Drug Application for Bystolic®
February 23, 2010
Additional indication not approved by FDA
Novartis Receives FDA Approval of Menveo(R), a Vaccine to Prevent Meningococcal Disease
February 22, 2010
Novartis plans to seek licensure of Menveo in infants and children 2-10 years of age
Merz to Complete Acquisition of BioForm Medical
February 19, 2010
Creates a Global Leader in Medical Aesthetics
GlaxoSmithKline and XenoPort Receive FDA Complete Response Letter for Horizant (GSK1838262/XP13512) for RLS
February 17, 2010
US FDA Denies Approval of Horizant for RLS
Mission Pharmacal Launches New Formulation of Kidney Stone Treatment, Urocit(R)-K 15 mEq
February 17, 2010
Maximum-strength, more convenient option available to help increase patient compliance
Javelin Pharmaceuticals' Receives FDA PDUFA Date for Dyloject NDA
February 17, 2010
Filed NDA for Management of Acute Moderate-to-Severe Pain
Abbott Completes Acquisition of Solvay Pharmaceuticals
February 16, 2010
Abbott Pays $6.2 Billion for Solvay Pharmaceuticals
FDA Approves Benicar(R) for the Treatment of High Blood Pressure in Children and Adolescents aged 6-16
February 11, 2010
New Treatment Option Available for the Rapidly Growing Population of Children Suffering From High Blood Pressure
Alexza and Biovail Form Collaboration to Develop and Commercialize AZ-004 (Staccato(R) Loxapine) in North America
February 10, 2010
Alexza to get upfront cash payment $40 Million
Adeona Appoints James S. Kuo, M.D., M.B.A., as Chairman, CEO and President
February 09, 2010
Company Intends to Launch and Establish Corporate Partnerships for Its Products
ADVENTRX Announces Management Promotions
February 04, 2010
Brian M. Culley will serve as Chief Executive Officer
Noven Appoints Patrick Gallagher as Vice President of Business Development
February 03, 2010
Gallagher has over 25 years' experience in the pharmaceutical, biotechnology and drug delivery industries
Labopharm Receives FDA Approval For OLEPTRO(TM)
February 03, 2010
Second U.S. FDA Product Approval in Just Over a Year For Labopharm's CONTRAMID(R) Controlled Release Technology
Allergan, Inc. Announces FDA Approval of JUVÉDERM® XC Dermal Filler Formulated with Lidocaine
February 01, 2010
Approved to Last up to One Year from Initial Treatment
GSK's TYKERB(R) Receives Accelerated Approval for First-Line Combination Treatment of Metastatic Breast Cancer
January 29, 2010
TYVERB in European markets, is currently being reviewed by the EMEA for a comparable indication
QuantRx Biomedical to Acquire NuRx Pharmaceuticals
January 29, 2010
Combination Strengthens Financial and Competitive Position
Latest News
Portola Pharmaceuticals Announces Senior Management and Board Changes
Neoprobe Announces Successful Meeting on Lymphoseek Phase 3 Results
Pfizer Discontinues A Phase 3 Study Of Figitumumab In Previously Treated Patients With Advanced Non-Small Cell Lung Cancer
Abbott Enhances Pharmaceutical Pipeline with Acquisition of Facet Biotech
Abbott Receives U.S. FDA Approval for New Cataract Multifocal Intraocular Lens
Affymax® Receives $5 Million Milestone Payment on Initiation of Phase 3 Clinical Trials for Hematide in Japan
Alun Malone Joins Millennium Laboratories As New Business Development Executive
Lilly to Acquire European Rights to Pfizer Animal Health Assets
CSL Behring Receives FDA Approval of Hizentra™
EKR Therapeutics Appoints John Bailye as Interim President & Chief Executive Officer
Most Popular
Most Emailed
Most Recent
Columbia Laboratories Enters into Purchase and Collaboration Agreement with Watson Pharmaceuticals for Progesterone Franchise
FDA Approves Exalgo Extended-Release Tablets
Astellas Pharma Inc. Commences Tender Offer to Acquire All Outstanding Shares of OSI Pharmaceuticals for $52 per Share in Cash
Transdel Pharmaceuticals Appoints Terry Nida as Chief Business Officer
CSL Behring Receives FDA Approval of Hizentra™
Shire Announces FDA Approval of VPRIV(TM) (velaglucerase alfa for injection) for the Treatment of Type 1 Gaucher Disease
EKR Therapeutics Appoints John Bailye as Interim President & Chief Executive Officer
Pfizer And Medivation Announce Results From Two Phase 3 Studies In Dimebon (latrepirdine*) Alzheimer's Disease Clinical Development Program
Novo Nordisk Receives FDA Approval for Norditropin(R) FlexPro(R) for Growth Hormone Treatment
Astellas Pharma Inc. Offers to Acquire OSI Pharmaceuticals for $52.00 Per Share in Cash
Novo Nordisk Receives FDA Approval for Norditropin(R) FlexPro(R) for Growth Hormone Treatment
FDA Advisory Committee Recommends Approval Of XIFAXAN® (rifaximin) Tablets, 550 Mg for Maintenance of Remission of Hepatic Encephalopathy
Pfizer Discontinues A Phase 3 Study Of Figitumumab In Previously Treated Patients With Advanced Non-Small Cell Lung Cancer
Neoprobe Announces Successful Meeting on Lymphoseek Phase 3 Results
Portola Pharmaceuticals Announces Senior Management and Board Changes
Affymax® Receives $5 Million Milestone Payment on Initiation of Phase 3 Clinical Trials for Hematide in Japan
Abbott Receives U.S. FDA Approval for New Cataract Multifocal Intraocular Lens
Abbott Enhances Pharmaceutical Pipeline with Acquisition of Facet Biotech
Lilly to Acquire European Rights to Pfizer Animal Health Assets
Alun Malone Joins Millennium Laboratories As New Business Development Executive
Portola Pharmaceuticals Announces Senior Management and Board Changes
Neoprobe Announces Successful Meeting on Lymphoseek Phase 3 Results
Pfizer Discontinues A Phase 3 Study Of Figitumumab In Previously Treated Patients With Advanced Non-Small Cell Lung Cancer
Abbott Enhances Pharmaceutical Pipeline with Acquisition of Facet Biotech
Abbott Receives U.S. FDA Approval for New Cataract Multifocal Intraocular Lens
Affymax® Receives $5 Million Milestone Payment on Initiation of Phase 3 Clinical Trials for Hematide in Japan
Alun Malone Joins Millennium Laboratories As New Business Development Executive
Lilly to Acquire European Rights to Pfizer Animal Health Assets
CSL Behring Receives FDA Approval of Hizentra™
EKR Therapeutics Appoints John Bailye as Interim President & Chief Executive Officer
Popular Topics
Acquisition
Agency
Animal Health
Biopharmaceutical
Biotech
Business
Clinical Management
Collaboration
Marketing & Communications
Medical Device
Medical Equipment
Merger
New Company
New Hire
New Hires
Personnel
Pharmaceutical
Pharmaceutical Marketplace
Pharmaceutical Products
Pipeline
Product Acquisition
Product Launch
Product Promotion
Regulatory
Research & Development